RFX6 and diabetes mellitus: Variants in RFX6 have lower levels of gastric inhibitory polypeptide hormone; this is in contrast to other forms of MODY or common forms of diabetes but is in keeping with the mouse model data.13 The discovery of RFX6-MODY was thus the first human form of diabetes associated with decreased gastric inhibitory polypeptide secretion.